$125 Million

Milestone Pharmaceuticals

Debt Advisory

Exclusive Financial Advisor, March 2023

Milestone Pharmaceuticals
Received Financing Through $50M in Convertible Notes and $75M in a Synthetic Royalty Sale

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines. Milestone’s lead product candidate etripamil recently completed its Phase 3 clinical-stage program for the treatment of paroxysmal supraventricular tachycardia (PSVT) and is in a Phase 2 proof-of-concept trial for the treatment of patients with atrial fibrillation with rapid ventricular rate (AFib-RVR). Milestone Pharmaceuticals operates in Canada and the United States.

More Like This

Jul 2023

Senior Secured Term Loan

Exclusive Placement Agent

View Details >
Jun 2023
$390 Million

Royalty Monetization

Exclusive Financial Advisor

View Details >
Apr 2023

Acquisition and Financing of Shapiro Aesthetic Plastic Surgery & Skin Klinic

Exclusive Financial Advisor

View Details >